白血病人工智能项目(LEAP)在慢性期慢性髓性白血病中:改善患者结局的模型
本研究采用极端梯度提升决策树方法开发LEAP模型,用于为慢性期慢性髓性白血病(CML-CP)患者提供酪氨酸激酶抑制剂(TKI)的最优治疗推荐。队列随机分为训练/验证集(N=504)和测试集(N=126),使用诊断时101个变量建模,测试集AUC为0.81899。根据LEAP推荐选择治疗与更好的生存概率相关。
要点
- LEAP模型基于诊断时101个变量,为CML-CP患者推荐最优TKI治疗。
- 测试集AUC为0.81899,显示模型具有较好的预测性能。
- 遵循LEAP推荐治疗与更好的生存概率相关。
核心结论
- LEAP CML-CP模型可为慢性期慢性髓性白血病患者提供个体化TKI治疗推荐,遵循推荐与更好的生存概率相关。
研究设计与样本
- 研究将CML-CP患者队列随机分为训练/验证集(N=504)和测试集(N=126),使用诊断时101个变量通过3折交叉验证开发LEAP CML-CP模型。
主要发现
- 测试集中LEAP CML-CP模型的AUC为0.81899。
- 多因素分析识别诊断时年龄、合并症程度和LEAP CML-CP模型推荐的TKI治疗为总生存的独立预后因素。
- Bootstrap法内部验证显示LEAP CML-CP推荐与总生存的关联为独立预后因素。
- 根据LEAP CML-CP个体化推荐选择治疗与更好的生存概率相关。
临床怎么用
- 临床可参考LEAP CML-CP模型为CML-CP患者制定个体化TKI治疗推荐,以可能改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extreme gradient boosting methods outperform conventional machine-learning models. Here, we have developed the LEukemia Artificial intelligence Program (LEAP) with the extreme gradient boosting decision tree method for the optimal treatment recommendation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP). A cohort of CML-CP patients was randomly divided into training/validation (N = 504) and test cohorts (N = 126). The training/validation cohort was used for 3-fold cross validation to develop the LEAP CML-CP model using 101 variables at diagnosis. The test cohort was then applied to the LEAP CML-CP model and an optimum TKI treatment was suggested for each patient. The area under the curve in the test cohort was 0.81899.Backward multivariate analysis identified age at diagnosis, the degree of comorbidities, and TKI recommended therapy by the LEAP CML-CP model as independent prognostic factors for overall survival. The bootstrapping method internally validated the association of the LEAP CML-CP recommendation with overall survival as an independent prognostic for overall survival. Selecting treatment according to the LEAP CML-CP personalized recommendations, in this model, is associated with better survival probability compared to treatment with a LEAP CML-CP non-recommended therapy. This approach may pave a way of new era of personalized treatment recommendations for patients with cancer.
引用
- Sasaki K, Jabbour EJ, Ravandi F, et al. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2020. PMID: 33180322. doi:10.1002/ajh.26047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。